These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Benzinga · 4d ago

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

The company posted adjusted earnings of $2.62 per share, beating market estimates of $1.98 per share. The company’s sales came in at $2.804 billion versus expectations of $2.632 billion.

Biogen narrowed its FY2026 adjusted EPS guidance from $15.85-$16.85 to $15.95-$16.75.

Biogen shares fell 0.3% to $243.34 in pre-market trading.

These analysts made changes to their price targets on Biogen following earnings announcement.

  • Needham analyst Ami Fadia maintained the stock with a Buy and raised the price target from $256 to $290.
  • Baird analyst Brian Skorney maintained the stock with an Outperform rating and raised the price target from $250 to $290.

Considering buying BIIB stock? Here’s what analysts think:

Photo via Shutterstock